Loading...
XNAS
EXAS
Market cap19bUSD
Dec 05, Last price  
101.06USD
1D
-0.07%
1Q
87.81%
Jan 2017
656.44%
IPO
585.15%
Name

Exact Sciences Corp

Chart & Performance

D1W1MN
XNAS:EXAS chart
P/E
—
P/S
6.94
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.01%
Rev. gr., 5y
25.78%
Revenues
2.76b
+10.37%
4,250,0004,750,0002,935,000-867,0004,758,0005,344,0004,163,0004,144,0004,144,0001,798,00039,437,00099,376,000265,989,000454,462,000876,293,0001,491,391,0001,767,087,0002,084,279,0002,499,766,0002,758,867,000
Net income
-1.03b
L+403.97%
-14,520,000-12,915,000-11,959,000-9,741,000-9,089,000-11,556,000-28,675,000-52,421,000-46,514,000-100,048,000-157,803,000-167,211,000-114,397,000-175,149,000-83,993,000-848,533,000-595,625,000-623,506,000-204,149,000-1,028,857,000
CFO
211m
+34.86%
-15,982,000-12,154,000-8,767,000-7,904,000-12,640,000-13,478,000-27,824,000-44,155,000-39,295,000-80,912,000-134,017,000-130,066,000-71,724,000-69,325,000-115,010,000136,482,000-102,236,000-223,559,000156,119,000210,536,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
URL
https://www.exactsciences.com/
IPO date
Jan 30, 2001
Employees
6,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT